Nle4-D-Phe7-alpha-MSH ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
254ポルフィリン症1

254. ポルフィリン症


臨床試験数 : 72 薬物数 : 53 - (DrugBank : 16) / 標的遺伝子数 : 19 - 標的パスウェイ数 : 35
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2007-000636-13-IT
(EUCTR)
27/07/200715/04/2008A Phase III, Multicentre, Randomised, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Bioresorbable CUV1647 Implants in Patients with Erythropoietic Protoporphyria (EPP) - Multicentre Phase III EPP StudyA Phase III, Multicentre, Randomised, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Bioresorbable CUV1647 Implants in Patients with Erythropoietic Protoporphyria (EPP) - Multicentre Phase III EPP Study Erythropoietic Protoporphyria (EPP)
MedDRA version: 9.1;Level: LLT;Classification code 10036181;Term: Porphyria
Product Name: CUV1647
INN or Proposed INN: Nle4-D-Phe7-alpha-MSH
CLINUVEL PHARMACUETICALS LTDNULLNot RecruitingFemale: yes
Male: yes
80Phase 3Germany;United Kingdom;Netherlands;France;Italy;Sweden